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A total of 45 primary head and neck squamous cell carcinomas were analysed by comparative genomic hybridisation to identify
regions of chromosomal deletion and gain. Multiple regions of copy number aberration were identified including gains affecting
chromosomes 3q, 8q, 5p, 7q, 12p and 11q and deletion of material from chromosomes 3p, 11q, 4p, 5q, 8p, 10q, 13q and 21. Kaplan–
Meier survival analysis revealed significant correlations between gain of 3q25–27 and deletion of 22q with reduced disease-specific
survival. In addition, gain of 17q and 20q, deletion of 19p and 22q and amplification of 11q13 were significantly associated with
reduced disease-free survival. A Cox proportional hazards regression model identified deletion of 22q as an independent prognostic
marker. The data presented here provide further evidence that the creation of a genetically based tumour classification system will
soon be possible, complementing current histopathological characterisation.
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Head and neck squamous cell carcinoma (HNSCC) is the fifth most
common cancer worldwide and contributes significantly to the
morbidity and mortality associated with human cancer. Despite
numerous advances in treatment the long-term survival rates for
HNSCC have changed little over the last 20 years (Jemal et al,
2003). Currently, the management of HNSCC is based on the
assessment of a variety of clinical and pathological parameters, of
which nodal status conveys the strongest prognostic information
(O’Brien et al, 1986). However, in many instances, these factors fail
to predict accurately the clinical behaviour of an individual
patient’s tumour. A greater understanding of the molecular basis
of HNSCC will hopefully allow the biological properties of an
individual patient’s tumour, including metastatic potential,
response to therapy and likelihood of recurrence, to be more
precisely determined.
Definition of the genetic changes underlying HNSCC is under-
way but remains incomplete. Classical cytogenetic analysis of
HNSCC tumours has revealed multiple chromosomal abnormal-
ities and highly complex karyotypes. The most widely reported
aberration demonstrating a correlation with clinical outcome is
amplification of chromosome 11q13. Both the amplification of this
band and overexpression of the cyclin D1 oncogene have been
repeatedly associated with poor prognosis (Akervall et al, 1995;
Meredith et al, 1995). Many of the limitations of conventional
cytogenetic analysis have been overcome with the development of
molecular techniques including FISH and comparative genomic
hybridisation (CGH). Comparative genomic hybridisation is a
powerful technique that screens the entire tumour genome for
DNA sequence copy number alterations. Comparative genomic
hybridisation has previously been applied in several HNSCC
studies and has demonstrated a nonrandom pattern of genomic
aberrations including deletions of material from 3p, 4q, 5q, 9p, 18q
and gains involving 3q, 5p, 7p, 8q, 11q, 17q and 20q (reviewed in
Struski et al, 2002).
In this study, we have applied CGH to HNSCC patients in order
to characterise the chromosomal imbalances underlying this
disease and evaluated the prognostic significance of the aberra-
tions identified.
METHODS
Patients
Informed consent was obtained from all patients and local ethical
approval granted for the study. In total, 53 consecutive patients
undergoing surgery for a single primary HNSCC between April
1996 and November 2001 were included in this study. Biopsy-sized
specimens were obtained at the time of surgical resection, snap
frozen in theatre and stored at  801C until analysis. Specimens
were taken immediately adjacent to specimen sent for histopatho-
logical assessment and all samples were analysed by a single
pathologist. Several patients were excluded from the study cohort
for the following reasons: only specimens containing 470%
malignant cells upon pathological examination were included, as
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of the tissue specimen (n¼5 excluded). Patients who received
radiotherapy prior to surgical resection were excluded from the
cohort (n¼3 excluded) to avoid the inclusion of specimens
containing radiotherapy-induced genetic changes. None of the 53
patients had received preoperative chemotherapy. The clinico-
pathological details of the 45 patients analysed are detailed in
Table 1.
Comparative genomic hybridisation
DNA was extracted from either serial 20mm cryostat sections or
whole biopsy by proteinase K digestion followed by phenol–
chloroform extraction. DNA quality and purity were assessed by
electrophoresis and spectrophotometry at 260nm, and CGH was
performed essentially as described previously (Stafford et al, 1999).
All CGH reagents were obtained from Abbott Laboratories Ltd
(Maidenhead, UK). All experiments were performed in combina-
tion with both positive (DNA with known aberrations) and
negative (normal:normal hybridisation) control experiments. Sex
mismatching of test and reference DNA precluded the analysis of
the sex chromosomes. Deletions and gains of DNA were identified
whenever the CGH ratio profile exceeded thresholds established
through normal:normal hybridisations (0.85 and 1.15 respec-
tively).
Statistical analysis
Disease-specific survival time was calculated as the time between
the date of tissue acquisition (surgical resection) and death. Only
patients with cancer-specific death were included in the analysis
and patients alive at the time of last follow-up were censored
accordingly. Disease-free survival was defined as the time between
tissue acquisition and evidence of disease recurrence. For purposes
of statistical analysis local, regional or distant recurrence were
grouped together as disease recurrence. Survival analysis was
performed using the Kaplan–Meier method and the difference in
survival curves was tested for statistical significance using the log
rank test. Cox proportional hazard analysis was used to test
variables identified by Kaplan–Meier analysis for independent
prognostic significance. The w
2 test was used to evaluate relation-
ships between categories. All statistical analysis was performed
using the SPSS version 10 software package and values of Po0.05
were considered to be statistically significant.
RESULTS
Overview of genomic changes in HNSCC
Genetic aberrations were detected in all 45 specimens analysed and
occurred across the entire genome. Figure 1 summarises all the
chromosomal aberrations identified. Overall, CGH identified a
complex pattern of aberrations; however, several frequent
chromosomal loci of copy number change were seen. These
included gains affecting chromosomes 3q, 8q, 5p, 7q, 12p and 11q
and deletion of material from chromosomes 3p, 11q, 4p, 5q, 8p,
10q, 13q and 21. Those occurring in 420% of the cohort of
tumours analysed are highlighted in Table 2 and are consistent
with previously published CGH analyses of HNSCC. There was a
mean of 18.8 aberrations per tumour (range 4–38), 9.4 deletions
(range 1–23) and 9.5 gains (range 1–18). Amplifications (CGH
ratio 41.5) were detected on 3q (10 cases), 11q (four cases), 5p
(two cases), 7p and 8q (one case each). There was no significant
difference between the total number of copy number aberrations
when patients were stratified by T stage, nodal involvement,
tumour stage or differentiation. Only gain of 7p and deletion of 9q
were significantly more frequent in patients with nodal involve-
ment (P¼0.019 and 0.012 respectively) and gain of 20q
significantly associated with recurrent disease (P¼0.022).
Clinical outcome
Follow-up of the patients was continued until November 2002 and
was available for all patients. The mean duration of follow-up was
35.0 months overall (95% confidence interval (CI), 28.3–41.7).
During this period, 37.8% of patients died from their disease
(mean time to death 20.0 months, 95% CI, 10.0–29.9) and 51.1%
patients developed disease recurrence (including six local, 14
regional, one local and regional and two distant recurrences; mean
time to disease recurrence 14.2 months, 95% CI, 8.6–19.7). Mean
follow-up for patients remaining alive at time of analysis was 44.0
months (95% CI, 36.9–51.2). The clinical outcome for patients
with pathologically proven regional lymph node metastases was
significantly worse than for patients with no nodal involvement
with a mean survival of 43.9 months (95% CI, 33.5–54.2) and 63.9
months (95% CI, 51.1–75.4) respectively (P¼0.024; Figure 2A).
When this analysis was extended to include patients who were not
initially submitted for a neck dissection, but eventually presented
with a neck recurrence (n¼3 additional tumours), this association
was slightly stronger with a mean survival of 44.4 months (95% CI,
34.6–54.1) for all patients with nodal involvement and 66.7
months (95% CI, 55.5–78.0) for patients in which the regional
lymph nodes remained disease-free through the course of follow-
up (P¼0.021). The clinical and follow-up details of the eight
patients excluded for reasons detailed in the Methods section did
not differ significantly from the cohort of 45 patients for which
genetic analysis was performed (data not shown).
Correlation of CGH data with survival
When disease-free survival was analysed, several aberrations
demonstrated significant associations (Table 3). Gain of 3q25–27
and losses on 22q were the only aberrations significantly
Table 1 Clinicopathological details of the 45 HNSCC patients included
in this study
Total Alive Dead of disease
No. of patients 45 28 17
Male 35 22 13
Female 10 6 4
Tumour site
Larynx 21 15 6
Hypopharynx 13 9 4
Oropharynx/oral cavity 10 4 6
Parotid 1 0 1
Stage
T1 1 1 0
T2 12 8 4
T3 9 8 1
T4 23 11 12
N0 15 13 2
N+ 30 15 15
N1 8 5 3
N2 20 10 10
N3 2 0 2
Differentiation
Well 3 2 1
Moderate 18 11 7
Poor 22 14 8
Undifferentiated 2 1 1
N0¼no nodal involvement; N+¼with nodal involvement.
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mean survival for patients with gain of the chromosomal locus
3q25–q27 was significantly reduced (44.9 months) when compared
to those without (63.3 months) (P¼0.04; Figure 2B). Interestingly,
this significance did not hold when patients with gains anywhere
on 3q were compared with those without (P¼0.37; Figure 2C). The
association of deletion of 22q with reduced survival was stronger
(P¼0.01; Figure 2D); however, only eight patients in the cohort
demonstrated this deletion. Mean survival for patients with loss of
22q was 17.0 months compared with 54.9 months for those
without. Cox proportional hazard analysis indicated that nodal
status and deletion on 22q were independent prognostic variables
(Table 4).
DISCUSSION
Comparative genomic hybridisation analysis of this cohort of
tumours has provided further evidence for the importance of gain
of material on 3q in the development of HNSCC. The gain of
3q25–27 was the most prevalent gain detected in this cohort of
primary HNSCC. Kaplan–Meier survival analysis demonstrated a
significant association of 3q25–27 gain with reduced overall
survival; however, Cox regression analysis indicated this effect was
not independent. Several other CGH studies have identified 3q as a
consistent site of both gain of DNA and amplification (Bergamo
et al, 2000; Bockmu ¨hl et al, 2000; Hashimoto et al, 2001; Hermsen
et al, 2001; Singh et al, 2001). A similar association with survival
has previously been identified by Bockmu ¨hl et al (2000). In their
study of 113 primary HNSCC tumours, gain of material at 3q21–
q29 demonstrated a strong association (P¼0.006–log rank test)
with a reduced overall survival. The significance of the difference
between the region of chromosome 3q identified in this cohort
(3q25–27) and Bockmu ¨hl study (3q21–29) is unclear. Both studies
involved heterogenous populations of HNSCC tumours, a major
limitation of any HNSCC analysis; however, the overall sub-site
distribution was similar. The observed difference may simply
reflect the different methods of analysis employed. Bockmu ¨hl et al
used a CGH analysis software package that allowed integrated
statistical analysis of chromosomal alterations at each chromoso-
mal band throughout the genome (at the ISCN 400 band
resolution). In the cohort presented here, the region 3q25–27
represents the minimal region of overlap present in all tumours
demonstrating a gain on 3q2.
The gain of 3q has been reported in numerous tumour types,
most frequently in those of squamous origin, including HNSCC,
squamous lung carcinomas and cervical carcinoma. (Chujo et al,
2002; Struski, 2002). In squamous cell carcinoma of the uterine
cervix, the gain of 3q has been shown to define the transition from
severe dysplasia to invasive carcinoma (Heselmeyer et al, 1996).
The high frequency of 3q gains identified in the present study is
consistent with 3q gain being an early event in HNSCC
tumorigenesis. However, an early, essential, genetic requirement
for tumorigenesis would be unlikely to carry prognostic value as
demonstrated here and previously (Bockmu ¨hl et al, 2000).
Recently, Hashimoto et al (2001) have further delineated the
involvement of 3q gains in HNSCC tumorigenesis by demonstrat-
ing a correlation between amplification, as opposed to low level
gain, of 3q26–qter and tumour progression. Hashimoto identified
gain of 3q26–qter in 91% of tumours (n¼32), and amplification at
a significantly higher frequency in T4 tumours (70%) when
compared with T2 and T3 tumours (both 27%; Po0.05–Fisher’s
exact test). Using interphase FISH, Singh et al (2002) demonstrated
a significant increase in 3q26–q27 amplification from normal
mucosa (3%), premalignant mucosa (25%) to invasive cancer
(56%; Po0.01). This study also showed a significant increase in
tumour recurrence and cancer-related death when tumours were
stratified by 3q26–q27 copy number (normal, low-level and high-
level (44 ) amplification). It appears likely that multiple genes
within the region of 3q gain identified in this study are important
for HNSCC progression. Alterations in a gene(s) early in HNSCC
tumorigenesis may occur through low-level gains, while amplifica-
tion of additional genes may occur later in the progression of
HNSCC and perhaps characterise more aggressive tumours with a
worse prognosis.
Several candidate genes have been localised to 3q25–q27
including the FGF12 growth factor, cyclin L and PIK3CA (Redon
et al, 2001, 2002). PIK3CA encodes the p110 catalytic subunit of
10
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Figure 1 Summary of all chromosomal gains and losses identified in 45 primary HNSCC tumours by CGH. Lines to the left of the chromosome
ideograms represent regions of deletion and lines to the right represent gains. The relative lengths of each line represents the size of the region of gain or
loss. All CGH ratio deviations identified using the thresholds detailed in the methods were included. A few, particularly small, regions of copy number change
below the accepted resolution of CGH (B10Mb) are present and care should be taken in interpreting these.
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signalling pathways including those of EGF and PDGF (Volinia
et al, 1994). Targeted FISH experiments using yeast artificial
chromosomes (YACs) have demonstrated amplification of the
PIK3CA gene in a panel of HNSCC cell lines (Singh et al, 2001).
Increased copy number of the PIK3CA gene has also been
identified in cervical cancer and ovarian cancer, and in the latter
case has been shown to be associated with increased expression
(Shayesteh et al, 1999; Ma et al, 2000).
The literature on the involvement of 22q in HNSCC progression
is limited. Comparative genomic hybridisation analysis has
demonstrated copy number changes in up to 50% of cases
analysed with both deletion and, more commonly, gain of material
from 22q having been reported. Preliminary LOH data have
proposed that allelic imbalance on 22q is more frequent in
laryngeal and oral tumours than other HNSCC (dos Reis et al,
2002). Comparative genomic hybridisation analysis of 22q, along
with regions of 1p, 9p, 16 and 19 can be problematic and should be
interpreted with caution (Jeuken et al, 2002). Particularly stringent
evaluation of simultaneous negative control experiments is
required to identify experimental artefact within this region. All
relevant negative control experiments were of a high quality and
did not demonstrate false-positive aberrations. In the 45 HNSCC
tumours reported here, deletion of 22q was a relatively infrequent
finding occurring in only eight cases; however, the clinical
outcome for these patients was particularly poor. Recently, a
study of 40 primary oral tumours by quantitative reverse
transcriptase–polymerase chain reaction (RT–PCR) identified
deletion of the DIA 1 gene, a cytochrome b5 reductase, at 22q13
in 25% of cases and this loss was also significantly associated with
a decrease in survival (P¼0.0018–log rank test; Reis et al, 2002).
One surprising result from this analysis was the low frequency of
11q13 amplification detected in this cohort of tumours (four out of
45), compared with other studies. To some extent, this may reflect
potential dilution of the CGH signal by normal cell contamination
as well as the arbitrary discrimination between gain (CGH ratio
1.15–1.5) and amplification (ratio41.5). Unlike Bockmu ¨hl et al
(2000), no association between gain of 11q13 and reduced survival
was identified; however, when tumours demonstrating amplifica-
tion of this region were analysed separately a strong association
with reduced disease-free survival was revealed. This association
with 11q13 amplification and poor prognosis is consistent with
previous classical karyotypic data (Akervall et al, 1995; Meredith
et al, 1995).
The demonstration of genetic aberrations exhibiting prognostic
significance in this relatively small cohort of tumours, using a low-
resolution technology, provides strong encouragement for the
continued investigation of the molecular abnormalities underlying
HNSCC and other tumours. Such findings demonstrate that
molecular characterisation of HNSCC can provide additional
markers of prognosis to supplement the classical pathological
assessment of tumours. It is important to emphasise that, as with
many other HNSCC studies, this cohort consisted of a mixed
Table 2 Frequencies of copy number imbalances identified in this study
(420% of cases), ranked according to the most frequently occurring
Chromosome Aberration Frequency (%)
3q25–q27 Gain 75.5
3q21–q24 Gain 62.2
8q22.2–qter Gain 55.6
3p24–pter Deletion 51.1
11q23.1–qter Deletion 48.9
8q21.1–q22.2 Gain 48.9
3qcen–q13.3 Gain 46.7
8qcen–q21.1 Gain 46.7
5p Gain 44.4
4p14.1–pter Deletion 42.2
3p13–p13.3 Deletion 40.0
5q32–qter Deletion 37.8
8p12–pter Deletion 35.6
7p12–q11.23 Gain 35.6
12p Gain 35.6
11q13.1–q14.1 Gain 35.5
21 Deletion 35.5
3p21.3–p23 Deletion 33.3
10q24.1–qter Deletion 33.3
13q22–qter Deletion 33.3
1q23–q31 Gain 31.1
4qcen–q21.3 Gain 31.1
4q32–qter Deletion 28.9
18q22–qter Deletion 28.9
9q33–qter Deletion 26.7
6qcen–q16.1 Gain 24.4
1p35–pter Deletion 24.4
11p14–pter Deletion 24.4
2q36–qter Deletion 24.4
18q11.2 Gain 24.4
9q13–q22.2 Gain 22.2
18p Gain 22.2
19p13.2–pter Deletion 22.2
7q31.3–qter Deletion 22.2
10p14–qter Deletion 22.2
12q21.2–q21.3 Gain 22.2
14q13–q21 Gain 20.0
9p21–pter Deletion 20.0
15q11.2–q15 Deletion 20.0
Table 3 Chromosomal aberrations demonstrating a significant association with disease-free (upper) and disease-specific survival (lower)
Mean survival (months)
Chromosome Aberration Log rank (P) No. of cases with aberration With aberration Without aberration
Disease-free survival
Nodal status — 0.039 30 (N+) 33.4 (N0) 54.2
17q Gain 0.049 9 10.9 44.4
20q Gain 0.001 5 4.6 46.1
19p Deletion 0.002 11 13.5 44.9
22q Deletion 0.004 8 8.7 45.2
11q13 Amplification 0.001 4 3.7 44.1
Disease-specific survival
Nodal status (at surgery) — 0.024 30 (N+) 43.9 (N0) 63.9
3q25–27 Gain 0.043 34 44.9 63.3
22q Deletion 0.011 8 17.0 54.9
N+¼with nodal involvement; N0¼without nodal involvement.
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significance of the findings presented here, but suggests that
additional studies on homogeneous populations of HNSCC
tumours may reveal additional subsite-specific genetic markers
of prognosis, which are masked when analysed as a single entity.
Many of the chromosomal regions identified in this study
contain tumour genes already implicated in the tumorigenesis of
HNSCC including 3p14 (fhit), 7p12 (EGFR), 7q31 (ING3), 8q24
(c-myc), 9p (p16), 11q13 (ccnd1) and 17p (p53). The affected genes
in other regions identified in this, and other studies, remain to be
fully elucidated. The body of knowledge of genetic aberrations in
HNSCC is rapidly growing, and with the advent of DNA
microarray technology the copy number and gene expression
levels of hundreds of genes can be accurately established.
Performing CGH on an ordered array of genomic clones, in place
of metaphase chromosomes, dramatically increases the resolution
of the technique. This modification of the CGH method has
demonstrated copy number changes as low as 100kb (Solinas-
Toldo et al, 1997). Such a significant increase in resolution and
sensitivity may help resolve discrepancies between CGH studies,
that is, regions such as 11q13 that correlate with prognosis in some
studies but not others. Microarray-based strategies represent the
future of gene copy number analysis in HNSCC and the
identification of chromosomal regions with prognostic importance
will facilitate the design of such higher resolution strategies,
allowing further molecular characterisation of this disease.
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